Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)

NCT00239980 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

77

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: dalteparin

Sponsor

Ontario Clinical Oncology Group (OCOG)

Collaborators

[object Object]